By David Gross
Immuno-oncology remains a favorite area of VC investment, as well for real estate given how much space many I-O developers require. Immunitas, backed by Novartis and Bayer, announced a $58 million Series B today to prepare its checkpoint inhibitors for the clinic. The funding follows $39 million Series A raised in 2019.
Immunitas is headquartered at King Properties' 130 Winter Street building in Waltham, MA. Other tenants there include TScan Therapeutics, Immunogen, and Dyne Therapeutics, who is subleasing there for $51 per square foot.